Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07172724 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial to Evaluate the Safety and Immunogenicity of the Vivaxin Vaccine for Malaria Caused by Plasmodium Vivax."

Study acronym: Vivaxin-001
StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 15, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Phase 1 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of a malaria vaccine named Vivaxin against the protozoan Plamodium vivax in participants with no prior malaria infection
Trial Details
NCT Number NCT07172724
Lead Sponsor Federal University of Minas Gerais
Collaborators: University of Sao Paulo, Financiadora de Estudos e Projetos, Fundação de Amparo à Pesquisa do Estado de São Paulo, INCTV National Institute of Vaccine Science and Technology, The Ministry of Science, Technology and Innovation, Brazil, CT Vacinas - Centro de Tecnologia em Vacinas/Universidade Federal de Minas Gerais
Conditions
(from sponsor)		 Malaria Vivax
Related terms Malaria, Malaria, Vivax
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov